Company profile: Allegro Ophthalmics
1.1 - Company Overview
Company description
- Provider of integrin inhibition therapy focused on retinal diseases, including Risuteganib (Luminate), an investigational compound targeting mitochondrial dysfunction and oxidative stress to restore retinal homeostasis for intermediate dry age-related macular degeneration, and ALG-1007, a topical mitochondrial stabilizer in development for dry eye disease with promising clinical trial results.
Products and services
- ALG-1007: A topical mitochondrial stabilizer in development for treating dry eye disease, showing promising results in clinical trials
- Risuteganib (Luminate): An investigational-stage compound targeting oxidative stress pathways to restore retinal homeostasis, primarily for intermediate dry age-related macular degeneration therapy
- Risuteganib (Luminate®): An investigational compound addressing mitochondrial dysfunction and oxidative stress to restore retinal homeostasis, developed primarily for intermediate dry age-related macular degeneration management
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Allegro Ophthalmics
ZymoGenetics
HQ: United States
Website
- Description: Provider of therapeutic protein discovery, development, and early manufacturing, supported by fully integrated research and development capabilities in scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, and clinical expertise; with an early focus on production systems for recombinant proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ZymoGenetics company profile →
Merus Labs
HQ: Canada
Website
- Description: Provider of pharmaceutical products across broad therapeutic classes, leveraging an opportunistic product acquisition strategy to source acquisition candidates and access targets not available to other players.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Merus Labs company profile →
AstraZeneca
HQ: United Kingdom
Website
- Description: Provider of biopharmaceutical research, development, manufacturing, and marketing of prescription medicines across oncology; cardiovascular, renal and metabolism; respiratory and immunology; vaccines and immune therapies; and rare diseases. Portfolio includes therapies such as datopotamab deruxtecan for advanced nonsquamous non-small cell lung cancer, with clinical trial survival benefits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AstraZeneca company profile →
Herborium
HQ: United States
Website
- Description: Provider of botanical therapeutics that develops, licenses, and markets proprietary botanical-based medicinal products. Offerings include AcnEase, a herbal acne and rosacea treatment; the Virtual Institute for Natural and Complementary Medicine, an educational platform for integrative medicine; the Kamasutra Spirits product line; and Herborium Botanical Therapeutics addressing dermatological needs and sexual disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Herborium company profile →
Woolsey Pharmaceuticals
HQ: United States
Website
- Description: Provider of investigational oral fasudil (BRAVYL) for indications including dementia-related wandering, Progressive Supranuclear Palsy, Corticobasal Syndrome, and Amyotrophic Lateral Sclerosis; conducts phase 2a studies (FOUND, REAL, ROCKIT-1) to evaluate efficacy, safety, and biomarkers; and maintains an expanded access policy for serious or life-threatening conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Woolsey Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Allegro Ophthalmics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Allegro Ophthalmics
2.2 - Growth funds investing in similar companies to Allegro Ophthalmics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Allegro Ophthalmics
4.2 - Public trading comparable groups for Allegro Ophthalmics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →